Literature DB >> 17371229

The PI3K p110delta controls T-cell development, differentiation and regulation.

D T Patton1, F Garçon, K Okkenhaug.   

Abstract

PI3Ks (phosphoinositide 3-kinases) regulate diverse cellular functions such as metabolism, growth, gene expression and migration. The p110delta isoform of PI3K is mainly expressed in cells of the immune system and contributes to cellular and humoral immunity. In the thymus, p110delta and p110gamma play complementary roles in regulating the transition through key developmental checkpoints. In addition, p110delta regulates the differentiation of peripheral Th (helper T-cells) towards the Th1 and Th2 lineages. Moreover, p110delta is critical for Treg (regulatory T-cell) function. Here, we review the role of PI3Ks in T-cell development and function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371229     DOI: 10.1042/BST0350167

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  11 in total

1.  p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.

Authors:  Aditi Chaudhari; Daniel Krumlinde; Annika Lundqvist; Levent M Akyürek; Sashidhar Bandaru; Kristina Skålén; Marcus Ståhlman; Jan Borén; Yvonne Wettergren; Katarina Ejeskär; Victoria Rotter Sopasakis
Journal:  Mol Cell Biol       Date:  2015-07-13       Impact factor: 4.272

Review 2.  Phosphatidylinositol 3-kinase: the oncoprotein.

Authors:  Peter K Vogt; Jonathan R Hart; Marco Gymnopoulos; Hao Jiang; Sohye Kang; Andreas G Bader; Li Zhao; Adam Denley
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

3.  Phosphatidylinositol 3-kinase is a key mediator of central sensitization in painful inflammatory conditions.

Authors:  Sophie Pezet; Fabien Marchand; Richard D'Mello; John Grist; Anna K Clark; Marzia Malcangio; Anthony H Dickenson; Robert J Williams; Stephen B McMahon
Journal:  J Neurosci       Date:  2008-04-16       Impact factor: 6.167

Review 4.  Phosphatidylinositol-3,4,5-trisphosphate: tool of choice for class I PI 3-kinases.

Authors:  Rachel Schnur Salamon; Jonathan M Backer
Journal:  Bioessays       Date:  2013-07       Impact factor: 4.345

5.  The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel KCa3.1 and CD4 T-cells.

Authors:  Shekhar Srivastava; Lie Di; Olga Zhdanova; Zhai Li; Santosha Vardhana; Qi Wan; Ying Yan; Rajat Varma; Jonathan Backer; Heike Wulff; Michael L Dustin; Edward Y Skolnik
Journal:  Mol Biol Cell       Date:  2009-07-08       Impact factor: 4.138

6.  GRK2 mediates TCR-induced transactivation of CXCR4 and TCR-CXCR4 complex formation that drives PI3Kγ/PREX1 signaling and T cell cytokine secretion.

Authors:  Brittney A Dinkel; Kimberly N Kremer; Meagan R Rollins; Michael J Medlyn; Karen E Hedin
Journal:  J Biol Chem       Date:  2018-07-17       Impact factor: 5.157

7.  TNFR-associated factor 6 regulates TCR signaling via interaction with and modification of LAT adapter.

Authors:  Ji-Ji Xie; Jia-Qi Liang; Liang-Hui Diao; Amnon Altman; Yingqiu Li
Journal:  J Immunol       Date:  2013-03-20       Impact factor: 5.422

8.  Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma.

Authors:  Dalya R Soond; Fabien Garçon; Daniel T Patton; Julia Rolf; Martin Turner; Cheryl Scudamore; Oliver A Garden; Klaus Okkenhaug
Journal:  J Immunol       Date:  2012-05-18       Impact factor: 5.422

9.  Immunomodulation of Selective Naive T Cell Functions by p110δ Inactivation Improves the Outcome of Mismatched Cell Transplantation.

Authors:  Jean-Marc Doisne; Christian M Hüber; Klaus Okkenhaug; Francesco Colucci
Journal:  Cell Rep       Date:  2015-02-05       Impact factor: 9.423

10.  The Antitumor Effect of Xihuang Pill on Treg Cells Decreased in Tumor Microenvironment of 4T1 Breast Tumor-Bearing Mice by PI3K/AKT~AP-1 Signaling Pathway.

Authors:  Xin-Ye Li; Liang Su; Yi-Ming Jiang; Wen-Bin Gao; Chun-Wei Xu; Chang-Qian Zeng; Jie Song; Yu Xu; Wen-Cai Weng; Wen-Bo Liang
Journal:  Evid Based Complement Alternat Med       Date:  2018-04-23       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.